

## Press Release

**Matthias Link**  
Corporate Communications

Fresenius SE & Co. KGaA  
Else-Kröner-Straße 1  
61352 Bad Homburg  
Germany  
T +49 6172 608-2872  
F +49 6172 608-2294  
matthias.link@fresenius.com  
www.fresenius.com

May 3, 2019

### **Fresenius Kabi launches biosimilar adalimumab IDACIO® in Germany**

- IDACIO®\* is Fresenius Kabi's first biosimilar approved in all indications of the reference product\*\*
- IDACIO® will help to facilitate more patient access to effective treatment options in Europe\*\*\*

Fresenius Kabi, a global healthcare company that specializes in lifesaving medicines and technologies, announces today that the company is launching its first biosimilar medicine in Germany. IDACIO® is available in the following administration options: pre-filled syringe, pre-filled pen and the vial presentation.

This market introduction follows the European Commission (EC) granting marketing authorization for IDACIO® for all indications of the reference medicine in the areas of rheumatology, gastroenterology and dermatology.

"The launch of IDACIO® in Germany is an important milestone for our company and for all patients who will now have an additional option for access to high-quality treatment," said Dr. Michael Schönhofen, President Pharmaceuticals and Devices Division of Fresenius Kabi. "We have a heritage of devotion towards providing high-quality and affordable products while upholding our tradition of putting patients first, which we are now carrying forward into our biosimilars offering."

## **About IDACIO®**

IDACIO® was developed by Fresenius Kabi. The European Commission approved IDACIO® for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis including ankylosing spondylitis, psoriatic arthritis, adult and paediatric, plaque psoriasis, adult and adolescent hidradenitis suppurativa, adult and paediatric Crohn's disease, ulcerative colitis, adult and paediatric non-infectious uveitis<sup>1</sup>.

1 European Medicines Agency. Idacio. Summary of Product Characteristics:

[https://www.ema.europa.eu/en/documents/product-information/idacio-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/idacio-epar-product-information_en.pdf)

\* IDACIO® (adalimumab) is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries

\*\* Humira®, a registered trademark of AbbVie Biotechnology Ltd.

\*\*\* The decision of the European Commission is valid in all the 28 member countries of the European Union plus in the European Economic Area (EEA) countries Norway, Iceland and Liechtenstein

# # #

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients. Fresenius Kabi's product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. Within transfusion and cell technologies, Fresenius Kabi offers products for collection and processing of blood and cell components.

With its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.

Fresenius Kabi employs over 37,000 people worldwide. In 2018 the company reported sales of more than €6.5 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group.

For more information visit the company's website at [www.fresenius-kabi.com](http://www.fresenius-kabi.com)

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius Kabi does not undertake any responsibility to update the forward-looking statements in this release.

Management Board: Mats Henriksson (Chairman), Marc Crouton, John Ducker, Chris Harrison, Dr. Christian Hauer, Dr. Michael Schönhofen, Gerrit Steen  
Chairman of the Supervisory Board: Stephan Sturm  
Registered Office: Bad Homburg, Germany  
Commercial Register: Amtsgericht Bad Homburg - HRB 11654